Follistatin as a potent regulator of bone metabolism

Biomarkers

Volumn 15, Issue 7, 2010, Pages 563-574

  Gajos Michniewicz, A ^a   Piastowska, A W ^a   Russell, J A ^b   Ochedalski, T ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Bone morphogenetic proteins; Bones; Follistatin; Transforming growth factor ; activin

Indexed keywords

ACTIVIN; BONE MORPHOGENETIC PROTEIN; FOLLISTATIN; INHIBIN; THROMBOSPONDIN; TRANSFORMING GROWTH FACTOR BETA;

BONE GROWTH; BONE MASS; BONE METABOLISM; BONE METASTASIS; BONE MINERALIZATION; CALCIFICATION; CELL DIFFERENTIATION; CYTOKINE PRODUCTION; GENE EXPRESSION; HUMAN; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOPOROSIS; PROTEIN ANALYSIS; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REVIEW;

BONE AND BONES; BONE NEOPLASMS; FOLLISTATIN; HUMANS; OSTEOPOROSIS; TRANSFORMING GROWTH FACTOR BETA;

EID: 77958585592     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2010.495786     Document Type: Review

References (50)

1. Ageta H, Murayama A, Migishima R, Kida S, Tsuchida K, Yokoyama M, Inokuchi K. (2008). Activin in the brain modulates anxiety-related behavior and adult neurogenesis. PLoS ONE 3:1-8. (Pubitemid 351943832)
2. Amthor H, Christ B, Rashid-Doubell F, Kemp CF, Lang E, Patel K. (2002). Follistatin regulates bone morphogenetic protein-7 (BMP-7) activity to stimulate embryonic muscle growth. Dev Biol 243:115-27. (Pubitemid 34208407)
3. Bilezikjian LM, Leal AM, Blount AL, Corrigan AZ, Turnbull AV, Vale WW. (2003). Rat anterior pituitary folliculostellate cells are target of interleukin-1β and major source of intrapituitary fol-listatin. Endocrinology 144:732-40.
4. Centrella M, Casinghino S, Ignotz R, McCarthy T. (1992). Multiple regulatory efects by transforming growth factor-β on type I collagen levels in osteoblast enriched cultures from fetal rat bone. Endocrinology 131:2863-72.
5. Dalkin AC, Haisenleder DJ, Yasin M, Gilrain JT. (1996). Pituitary activin receptor subtypes and follistatin gene expression in female rats: diferential regulation by activin and follistatin. Endocrinology 137:548-54. (Pubitemid 26043749)
6. Dow AL, Russell DS, Duman RS. (2005). Regulation of activin mRNA and Smad2 phosphorylation by antidepressant treatment in the rat brain: efects in behavioral models. J Neurosci 25: 4908-16.
7. Dunn LK, Mohammad KS, Fournier PGJ, McKenna CR., Davis HW, Niewolna M, Peng XH, Chirgwin JM, Guise TA. (2009). Hypoxia and TGF-β drive breast cancer bone metastases through parallel signaling pathways in tumor cells and bone micro environment. Plos One 4:1-20.
8. Ebeling PR. (2006). Editorial: Inhibin in Bone-New Tricks for an Old Dog. J Clin Endocrinol Metab 91:1669-70.
9. Eijken M, Swagemakers S, Koedam M, Steenbergen C, Derkx P, Uitterlinden AG, van der Spek PJ, Visser JA, de Jong FH, Pols HAP, van Leeuwen JP. (2007). The activin A-follistatin system: potent regulator of human extracellular matrix mineralization. FASEB J 21:1-12. (Pubitemid 47372761)
10. Epstein R. (2005). Biologia Molekularna Człowieka. Metabolizm. Lublin: Czelaj Publisher.
11. Erlebacher A, Filvarof EH, Ye J-Q, Derynck R. (1998). Osteoblastic responses to TGF-β during bone remodeling. Mol Biol Cell 9:1903-18. (Pubitemid 28337531)
12. Filvarof E, Erlebacher A, Ye J, Gitelman SE, Lotz J, Heillman M, Derynck R. (1999). Inhibition of TGF-β receptor signaling in osteoblasts leads to decreased bone remodeling and increased trabecular bone mass. Development 126:4267-79. (Pubitemid 29509342)
13. Fournier PGJ, Guise TA. (2007). BMP 7: a new bone metastases prevention. AJP 171:739-43.
14. Funaba M, Ogawa K, Murata T, Fujimura H, Murata E, Abe M, Takahashi M, Torii K. (1996). Follistatin and activin in bone: expression and localization during endochondral bone development. Endocrinology 137:4250-8. (Pubitemid 26321873)
15. Fuller K, Bayley K, Chambers T. (2000). Activin A is essential cofactor for osteoblast induction. Biochem Biophys Res Comm 268:2-7. (Pubitemid 30116600)
16. Gaddy-Kurten D, Coker JK, Abe E, Jilka RL, Manolagas SC. (2002). Inhibin Suppresses and activin stimulates osteoblastogen-esis and osteoclastogenesis in murine bone marrow cultures. Endocrinology 143:74-83. (Pubitemid 34056405)
17. Grainger DJ, Percivial J, Chiano M, Spector TD. (1999). The role of serum TGF-beta isoforms as potential markers of osteoporosis. Osteopros Int 9:398-404. (Pubitemid 29231731)
18. Harrison CA, Gray PC, Vale WW, Robertson DM. (2005). Antagonists of activin signaling: mechanisms and potential biological applications. Trends Endocrinol Metab 16:73-8.
19. Hashimoto M, Shoda A, Inoue S, Yamada R, Kondo T, Sakurai T, Ueno N, Muramatsu M. (1992). Functional regulation of osteoblastic cells by the interaction of activin-A with follistatin. J Biol Chem 267:4999-104.
20. Ikenoue T, Jingushi S, Urabe K, Okazaki K, Iwamoto Y. (1999). Inhibitory efects of activin-A on osteoblasts diferentiation during cultures of fetal rat calvarial cells. J Cell Biochem 75:206-14. (Pubitemid 29463489)
21. Inoue S, Nomura S, Hosoi T, Ouchi Y, Orimo H, Muramatsu M. (1994). Localization of follistatin, an activin binding protein, in bone tissue. Calcif Tissue Int 55:395-7.
22. Kaiser UB, Chin WW. (1993). Regulation of follistatin messenger ribonucleic acid levels in rat pituitary. J Clin Invest 91:2523-31.
23. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordón-Cardo C, Guise TA, Massagué J. (2003). A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3:537-49. (Pubitemid 36808649)
24. Karczmarewicz E. (2000). Wartosc Diagnostyczna Markerów Obrotu Kostnego. Uzgodnienia. Available at: http://www.osteoforum. org.pl/markery.html (last accessed 1 June 2010).
25. Kawakami Y, Rodriguez-Leó J, Belmonte JCI. (2006). The role of TGFßs and Sox9 during limb chondrogenesis. Curr Opin Cell Biol 18:723-9. (Pubitemid 44692480)
26. Kochanowska I, Chaberek S, Wojtowicz A, Marczynski B, Włodarski K, Dytko M, Ostrowski K. (2007). Expression of genes for bone mor-phogenetic proteins BMP-2, BMP-4 and BMP-6 in various parts of the human skeleton. BMC Musculoskel Disord 8:1-10. (Pubitemid 351253133)
27. Kretser DM, Hedger MP, Phillips DJ. (1999). Activin A and follistatin: their role in acute phase reaction and infammation. J Endocrinol 161:195-8.
28. Krneta J, Kroll J, Alves F, Prahst C, Sananbenesi F, Dullin C, Kimmina S, Phillips DJ, Agustin HG. (2006). Dissociation of angiogenesis and tumorigenesis in follistatin-and activin-expressing tumors. Cancer Res 66:5686-95. (Pubitemid 43927121)
29. Leto G, Incorvaia L, Badalamenti G, Tumminello FM, Gebbia N, Flandia C, Crescimanno M, Rini G. (2006). Activin A circulating levels in patients with bone metastasis from Brest or prostate cancer. Clin Exp Metastasis 23:117-22. (Pubitemid 44440171)
30. Lin SY, Morrison JR, Phillips DJ, de Kretser DM. (2003). Regulation of ovarian function by the TGF-ß superfamily and follistatin. Reproduction 126:133-48.
31. McPherson SJ, Mellor SL, Wang H, Evans LW, Groome NP, Risbridger GP. (1999). Expression of activin A and follistatin core proteins by human prostate tumor cell lines. Endocrinology 140:5303-9. (Pubitemid 30660240)
32. Olakowski M. (2007). Rola czynników wzrostu w patogenezie raka trzustki. Czçsc II: Transformujacy czynnik wzrostu ß (TGF-β), czynnik wzrostu fbroblastów (FGF), czynnik wzrostu nerwów (NGF). Przegkfd Gastroenterologiczny 2:175-80.
33. Ostrowski K. (1995). Histologia, 2nd edn. Warszawa: PZWL.
34. Patel K. (1998). Molecules in focus: follistatin. Int J Biochem Cell Biol 30:1087-93.
35. Phillips DJ, Kretser DM. (1998). Follistatin: a multifunctional regulatory protein. Front Neuroendocrinol 19:287-322.
36. Perrien DS, Akel NS, Edwards PK, Carver AA, Bendre MS, Swain FL, Skinner RA, Hogue WR, Nicks KM, Pierson TM, Suva LJ, Gaddy D. (2007). Inhibin A is an endocrine stimulator of bone mass and strength. Endocrinology 148:1654-65. (Pubitemid 46457125)
37. Perrien DS, Achenbach SJ, Bledsoe SE, Walser B, Suva LJ, Khosla S, Gaddy D. (2006). Bone turnover across the menopause transition: correlations with inhibins and follicle-stimulating hormone. J Clin Endocrinol Metab 91:1848-54.
38. Risbridger GP, Mellor SL, McPherson SJ, Schmitt JF. (2001). The contribution of inhibins and activins to malignant prostate disease. Mol Cell Endocrinol 180:149-53.
39. Sakai R, Eto Y. (2001). Involvement of activin in the regulation of bone metabolism. Mol Cell Endocrinol 180:183-8. (Pubitemid 32645645)
40. Steiner MS. (1995). Review of peptide growth factors in benign prostatic hyperplasia and urological malignancy. J Urol 153:1085-96.
41. Tardif G, Hum D, Pelletier JP, Boileau C, Ranger P, Martel-Pelleter J. (2004). Diferential gene expression and regulation of the bone morphogenetic protein antagonist follistatin and gremlin in normal and osteoarthritic chondrocytes and synovial fbroblasts. Arthritis Rheum 50:2521-30. (Pubitemid 39062713)
42. Tompson TB, Lerch TF, Cook RW, Woodruf TK, Jardetzky TS. (2005). The structure of the follistatin: activin complex reveals antagonism of both type I and type II receptor binding. Dev Cell 9:535-43.
43. van Lenthe GH, Voide R, Boyd SK, Müller R. (2008). Tissue modulus calculated from beam theory is biased by bone size and geometry: implications for the use of three-point bending tests to determine bone tissue modulus. Bone 43:717-23.
44. Vänttinen T, Kuulasmaa T, Liu J, Voutilainen R. (2002). Expression of activin/inhibin receptor and binding protein genes and regulation of activin/inhibin peptide secretion in human adrenocorti-cal cells. J Clin Endocrinol Metab 87:4257-63.
45. Vukicevic S, Sampath K. (2004). Bone Morphogenetic Proteins: Regeneration of Bone and Beyond. Basel: Birkhäuser. p. 1-22.
46. Wan M, Cao X. (2005). BMP signaling in skeletal development. Biochem Biophys Res Commun 328:651-7. (Pubitemid 40208302)
47. Wang Q, Tabatabaei S, Planz B, Lin C-W, Sluss PM. (1999). Identifcation of an activin-follistatin growth modulatory system in the human prostate: secretion and biological activity in primary cultures of prostatic epithelial cells. J Urol 161: 1378-84. (Pubitemid 29426160)
48. Wankell M, Munz B., Hübner G, Hans W, Wolf E, Goppelt A, Werner S. (2001). Impaired wound healing in transgenic mice overexpress-ing the activin antagonist follistatin in the epidermis. EMBO J 20:5361-72. (Pubitemid 32959456)
49. Welt C, Sidis Y, Keutmann H, Schneyer A. (2002). Activins, inhibins and follistatins: from endocrinology to signaling. A paradigm for the new millennium. Exp Biol Med 227:724-52.
50. Xiao YT, Xiang LX, Shao JZ. (2007). Bone morphogenetic protein. Biochem Biophys Res Commun 362:550-3.